Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Clinical Trials Arena on MSN20d
FDA removes clinical hold on Entrada’s Duchenne therapyEntrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now that the US Food and Drug Administration (FDA) has lifted a two-year clinical ...
Clinical Trials Arena on MSN1d
Dyne’s DMD trial advances patient mobility and dystrophin expressionThe Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...
Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy ...
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in the U.S., the biotech has ...
A University of Alberta research team has taken the first step toward proving its innovative gene therapy can successfully ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback